Cite
HARVARD Citation
Reich, D. et al. (2021). Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet neurology. 20 (9), pp. 729-738. [Online].